Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH102 for the treatment of beta-thalassemia; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
What is the ticker symbol for Graphite Bio, Inc.? What does GRPH stand for in stocks?
GRPH is the stock ticker symbol of Graphite Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Graphite Bio, Inc. (GRPH)?
As of Wed Nov 27 2024, market cap of Graphite Bio, Inc. is 1.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of GRPH stock?
You can check GRPH's fair value in chart for subscribers.
Is Graphite Bio, Inc. a good stock to buy?
The fair value guage provides a quick view whether GRPH is over valued or under valued. Whether Graphite Bio, Inc. is cheap or expensive depends on the assumptions which impact Graphite Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GRPH.